Immuneel Therapeutics Private Limited

Immuneel Therapeutics Private Limited - healthcare in Bengaluru, Karnataka, India. FY 2026 financials & compliance.
CIN U24230KA2018PTC119691 Incorporated 20 December 2018 ROC Bangalore HQ Bengaluru, Karnataka, India
Active Private Limited Company healthcare DPIIT Startup MSME · Medium
Revenue · FY 2024
₹2.25 Cr
▼ 47% YoY
Net loss · FY 2024
₹53.77 Cr
Latest filing
EBITDA · FY 2024
-₹47.53 Cr
Latest filing
Authorised capital
₹100 Cr
Registered with MCA
Paid-up capital
₹4.64 Lakh
Issued & subscribed
Company age
8 yrs
Est. 2018
Employees · EPFO
93
Provident fund records
Directors on board
6
As per MCA filings

About Immuneel Therapeutics Private Limited

Data last updated:

Immuneel Therapeutics Private Limited is a private limited company based in Bengaluru, Karnataka, India, recognised as a startup by DPIIT. It operates in the oncology clinics and cancer treatment segment of the healthcare sector. It was incorporated on 20 December 2018 and has been in existence for over 8 years.

Its director Ranjan Pai is #57 among India's richest people (2026). Its director Kiran Mazumdar-Shaw is #102 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U24230KA2018PTC119691. Its GSTIN is 29AAFCI1086C1ZP (Karnataka).

The company has an authorised share capital of ₹100 Cr and a paid-up capital of ₹4.64 Lakh. It is led by directors including Kiran Mazumdar Shaw and Siddhartha Mukherjee.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 29/P2 8th Floor Narayana Health City Hosur Road Bommasandra Industrial Area, Bengaluru, Karnataka, India – 560099.

As per the financials filed for FY 2024, the company reported a revenue of ₹2.25 Cr, a decline of 47% compared to the previous year. For the same year it recorded a net loss of ₹53.77 Cr and EBITDA of -₹47.53 Cr. Revenue has declined at a compounded annual rate (CAGR) of 10% over three years.

The company has about 93 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Immuneel. Court records list 1 case involving the company, including 1 filed against it. The company has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹397.2 Cr; the latest was in June 2026. The company has 4 MSME Form 1 returns on record between 2022 and 2024, listing 55 overdue payments to 22 micro and small suppliers.

Immuneel Therapeutics Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-03-0230071). For more details, the company can be reached via its website immuneel.com.

Company details

CIN U24230KA2018PTC119691
Registration Number 119691
Incorporation Date 20 December 2018
ROC Bangalore
Listing Status Unlisted
Company Status Active
DPIIT Recognition Recognised Startup
MSME Classification Medium
Udyam Registration UDYAM-KR-03-0230071
Key People
Kiran Mazumdar Shaw Director Siddhartha Mukherjee Director Prem Venkatachalam Pavoor Director

Recognitions & Rankings of Immuneel Therapeutics

DPIIT recognised startup Government of India
Startup India
MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-KR-03-0230071

Contact details

Immuneel Therapeutics Private Limited's registered office is in Bengaluru, Karnataka. Its website is immuneel.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    immuneel.com
  • Social Media
  • Registered Address
    29/P2 8th Floor Narayana Health City Hosur Road Bommasandra Industrial Area, Bengaluru, Karnataka, India – 560099
  • Industry
    Healthcare, Oncology Clinics & Cancer Treatment

To see the full contact details of Immuneel Therapeutics Private Limited, buy the company report.

Comprehensive company report
Immuneel Therapeutics Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Immuneel Therapeutics operates one associated brand: Immuneel. Each brand links to its own profile.

BrandDescriptionWebsite
Immuneel
T-cell therapies for cancer treatment are developed using genetic engineering.immuneel.com

Business activity

The main business activity of Immuneel Therapeutics is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

Financials of Immuneel Therapeutics Private Limited

FY 2024 filings available

Immuneel Therapeutics Private Limited reported revenue of ₹2.25 Cr (down 47% YoY) for FY 2024.

Revenue · FY 2024
₹2.25 Cr ▼ 47%
Net loss · FY 2024
₹53.77 Cr
EBITDA · FY 2024
-₹47.53 Cr

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 47%
3 years · compounded
▼ 10%
EBITDA CAGR growth
1 year
▼ 36%
3 years · compounded
▼ 44%
5 years · compounded
▼ 205%

Revenue has declined at a compounded annual rate (CAGR) of 10% over three years, including a 47% fall in the latest year. EBITDA fell 36% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA-₹47.53 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹53.77 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin
Net Profit Margin
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Immuneel Therapeutics Private Limited, buy the company report.

Board of directors of Immuneel Therapeutics Private Limited

Immuneel Therapeutics has 6 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Kiran Mazumdar Shaw
Also directs: Glenloch Properties LLP, Biocon Limited, Trent Limited and 5 more
Director20 Dec 20187 Years 10 MonthsCurrent
Siddhartha MukherjeeDirector20 Apr 20224 Years 6 MonthsCurrent
Prem Venkatachalam Pavoor
Also directs: Laurus Bio Private Limited, Enzene Biosciences Limited, Caplin Steriles Limited and 3 more
Director20 Apr 20224 Years 6 MonthsCurrent
Ranjan Ramdas Pai
Also directs: Aarin Asset Advisors LLP, Memg Family Office LLP, Memg Fund Advisors LLP and 5 more
Director20 Dec 20187 Years 10 MonthsCurrent
Amit Mookim
Also directs: Tie India Foundation
Director06 Sep 20242 Years 2 MonthsCurrent
Saif Khalfan Mohamed Al HasaniDirector29 Aug 20242 Years 2 MonthsCurrent
View all directors

Auditor

Immuneel Therapeutics Private Limited is audited by S.R. BATLIBOI & ASSOCIATES LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
S.R. BATLIBOI & ASSOCIATES LLPFY 2023101049W/E300004

Shareholding

The shareholding of Immuneel Therapeutics Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2022FY 2021FY 2020FY 2019
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Immuneel Therapeutics Private Limited, buy the company report.

Deals & funding

Immuneel Therapeutics Private Limited has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹397.2 Cr; the latest was in June 2026.

Total deals
6
Funding rounds
3
Secondary share transfers
2
Convertible or debt financing
1
Disclosed funding
₹397.2 Cr

Deals on record (4 of 6)

WhenDealAmountParties
Jun 2026Funding round · Series B₹100 CrInvestors: Singularity AMC, Rainmatter Ventures, Eight Roads Ventures, an individual
Apr 2022Funding round · Series A₹108.21 CrInvestors: True North, F-Prime Capital Partners, Glentec International
Mar 2021Secondary share transferUndisclosedBuyer: Tenshi Life Sciences Private Limited
Seller: Agnus Capital
Jul 2019Secondary share transferUndisclosedBuyer: Immuneel Employees welfare Trust, 2 individuals
Seller: 2 individuals

To see the full deal history of Immuneel Therapeutics Private Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Immuneel Therapeutics Private Limited has 4 MSME Form 1 returns on record between 2022 and 2024, listing 55 overdue payments to 22 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 22)

SupplierAmount dueDue sinceReported on
Bi Biotech India Private Limited
an individual supplier
Cytocare Technologies Private Limited
Proteogen Biosciences (India) Private Limited
an individual supplier

To see the full MSME payment records of Immuneel Therapeutics Private Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Immuneel Therapeutics Private Limited has a workforce of 93 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
93
Active EPFO establishments
1
Employee growth
38.8%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-2793
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20

To see the full employee and EPFO history of Immuneel Therapeutics Private Limited, buy the company report.

GST

Immuneel Therapeutics has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
29AAFCI1086C1ZPKarnatakaActive24 Jul 2019

To see the full GST registrations and return filing status of Immuneel Therapeutics Private Limited, buy the company report.

Recent activity

Immuneel Therapeutics Private Limited has 8 board changes on record since 2018: 6 appointments and 2 cessations. The latest: Amit Mookim ceased to be Additional Director on 29 Sep 2024.

AGM
Immuneel Therapeutics Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Ceased
Amit Mookim ceased to be Additional Director.
Appointed
Amit Mookim was appointed as Director.
Appointed
Saif Khalfan Mohamed Al Hasani was appointed as Director.
Ceased
Arun Anand ceased to be Director.
Filing
Immuneel Therapeutics Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore.
Appointed
Prem Venkatachalam Pavoor was appointed as Director.
Appointed
Siddhartha Mukherjee was appointed as Director.
Appointed
Kiran Mazumdar Shaw was appointed as Director.
Appointed
Ranjan Ramdas Pai was appointed as Director.
Incorporation
20 Dec 2018
Immuneel Therapeutics Private Limited was registered on 20 Dec 2018 with Roc Bangalore & aged 7 years 10 months as per MCA records.

News

Frequently asked questions

Immuneel Therapeutics is an active private limited company based in Bengaluru, Karnataka, India. The company works in oncology clinics and cancer treatment, within the healthcare industry. It was incorporated on 20 December 2018 (8+ years old) and is registered under CIN U24230KA2018PTC119691.

Immuneel Therapeutics has 6 current directors:

The latest financial statements of Immuneel Therapeutics on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.

The GSTIN of Immuneel Therapeutics is 29AAFCI1086C1ZP, registered in Karnataka.

The CIN (Corporate Identification Number) of Immuneel Therapeutics is U24230KA2018PTC119691. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Immuneel Therapeutics has 1 court case on record: 1 filed against it.

Immuneel Therapeutics was incorporated on 20 December 2018, making it 8+ years old. It is registered with the Registrar of Companies, Bangalore.

Immuneel Therapeutics has 6 deals on record (3 funding rounds, 2 secondary share transfers, 1 convertible or debt financing), with disclosed funding of ₹397.2 Cr; the latest was in June 2026.

Amit Mookim ceased to be Additional Director on 29 Sep 2024. Amit Mookim was appointed as Director on 06 Sep 2024. Saif Khalfan Mohamed Al Hasani was appointed as Director on 29 Aug 2024. Immuneel Therapeutics has 8 board changes on record in total.

Yes, Immuneel Therapeutics is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).

Yes, Immuneel Therapeutics is registered as a medium enterprise under Udyam registration (number: UDYAM-KR-03-0230071).